AMENDMENT NO. 2 TO COMMON STOCK PURCHASE AGREEMENT BETWEEN Estrella Immunopharma, Inc. AND WHITE LION CAPITAL LLCCommon Stock Purchase Agreement • December 6th, 2024 • Estrella Immunopharma, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 2 TO COMMON STOCK PURCHASE AGREEMENT (this “Amendment”), effective December 4, 2024 (the “Amendment Effective Date”), is by and between Estrella Immunopharma, Inc., a Delaware corporation and f/k/a TradeUP Acquisition Corp. (the “Company”), and White Lion Capital, LLC, a Nevada limited liability company (the “Investor”), and amends the Common Stock Purchase Agreement by and between the Company and Investor dated April 20, 2023, as amended by that certain Amendment No. 1, dated as of April 26, 2023 (as amended, the “Agreement”), to permit the Company to effect sales to the Investor pursuant to Rapid Purchase Notices (as defined below). All capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Agreement.
